SCLX
Scilex Holding Company
NASDAQ · USHealthcareDrug Manufacturers - General
$7.64-9.48%
Price as of Jul 20, 2026
SCLX growth
Scilex Holding Company growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -33.2%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- +1123.9%
- EBITDA
- +6.0%
- EPS
- +110.6%
Three-year CAGR
- Revenue
- -7.3%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -87.8%
- Free cash flow
- -80.4%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.